Beahwa Yeoh, NP
Nurse Practitioner · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 20 years
- Graduated 2006
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Beahwa Yeoh’s office at (408) 885-5000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A16068 · Cancelled
Licence status: Cancelled · since 1954 · Ludwig-Maximilians-University of Munich Faculty of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$4,823 in 2024
Medicaid paid $4,823 for 314 billed services this clinician did in 2024, up to 23 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension | 23 | $1,284 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 17 | $676 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 17 | $656 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 23 | $373 |
| IAAD IA HEPATITIS B SURFACE ANTIGEN | 23 | $269 |
| HEPATITIS C ANTIBODY | 16 | $259 |
| Antibody; varicella-zoster | 16 | $227 |
| Assay for total hepatitis B core antibody (HBcAb) | 16 | $219 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 23 | $203 |
| Hepatitis B surface antibody (HBsAb) | 16 | $195 |
| TREPONEMA PALLIDUM | 16 | $146 |
| HEPATIC FUNCTION PANEL | 23 | $133 |
| 2024 | 314 | 16 | 23 | $4,823 |
| 2023 | 1,464 | 19 | 33 | $22,106 |
| 2022 | 310 | 17 | 22 | $13,507 |
| 2021 | 1,304 | 26 | 60 | $108,765 |
| 2020 | 63 | 2 | 20 | $17,950 |
See the largest Medicaid services in earlier years
2023
| Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension | 106 | $5,917 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 69 | $2,744 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 69 | $2,663 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 111 | $2,249 |
| IAAD IA HEPATITIS B SURFACE ANTIGEN | 111 | $1,299 |
| HEPATITIS C ANTIBODY | 65 | $1,052 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 108 | $953 |
| Assay for total hepatitis B core antibody (HBcAb) | 68 | $929 |
| Antibody; varicella-zoster | 65 | $921 |
| Hepatitis B surface antibody (HBsAb) | 67 | $815 |
| HEPATIC FUNCTION PANEL | 111 | $703 |
| TREPONEMA PALLIDUM | 69 | $629 |
2022
| Clinic visit/encounter, all-inclusive | 21 | $10,601 |
| Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension | 17 | $949 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 35 | $554 |
| IAAD IA HEPATITIS B SURFACE ANTIGEN | 18 | $211 |
| HEPATITIS C ANTIBODY | 13 | $210 |
| TREPONEMA PALLIDUM | 23 | $203 |
| Antibody; varicella-zoster | 12 | $170 |
| Assay for total hepatitis B core antibody (HBcAb) | 12 | $164 |
| Hepatitis B surface antibody (HBsAb) | 12 | $146 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 16 | $141 |
| HEPATIC FUNCTION PANEL | 17 | $102 |
| Creatinine; blood | 30 | $30 |
2021
| Clinic visit/encounter, all-inclusive | 203 | $98,819 |
| Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension | 51 | $2,847 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 99 | $1,563 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 25 | $994 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 25 | $965 |
| IAAD IA HEPATITIS B SURFACE ANTIGEN | 52 | $608 |
| TREPONEMA PALLIDUM | 59 | $517 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 49 | $432 |
| HEPATITIS C ANTIBODY | 21 | $340 |
| HEPATIC FUNCTION PANEL | 50 | $313 |
| Assay for total hepatitis B core antibody (HBcAb) | 20 | $273 |
| Antibody; varicella-zoster | 19 | $269 |
2020
| Clinic visit/encounter, all-inclusive | 39 | $17,950 |
| Short return visit | 24 | $0 |
Drugs they prescribed that Part D paid
$181,151
Pharmacies billed $181,151 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 408) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
129 generic and 261 brand-name prescriptions · $181,151 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 55 | $48,992 | $891 |
| Trulicity | 34 | $34,545 | $1,016 |
| Jardiance | 51 | $28,918 | $567 |
| Mounjaro | 13 | $13,181 | $1,014 |
| Synjardy Xr | 18 | $9,570 | $532 |
See all 12 drugs
| Ozempic | 55 | $48,992 | $891 |
| Trulicity | 34 | $34,545 | $1,016 |
| Jardiance | 51 | $28,918 | $567 |
| Mounjaro | 13 | $13,181 | $1,014 |
| Synjardy Xr | 18 | $9,570 | $532 |
| Xigduo Xr | 13 | $7,133 | $549 |
| Tradjenta | 14 | $5,734 | $410 |
| Rifampin | 18 | $731 | $41 |
| Ultra-Fine Short Pen Needle | 11 | $607 | $55 |
| Metformin Hcl Er | 43 | $325 | $8 |
| Isoniazid | 31 | $160 | $5 |
| Pioglitazone | 13 | $51 | $4 |
Year by year
| 2024 | 408 | 47 | 0% (0) | 64% | $181,151 |
| 2023 | 532 | 93 | 0% (0) | 55% | $233,599 |
| 2022 | 548 | 75 | 0% (0) | 65% | $252,135 |
| 2021 | 415 | 63 | 0% (0) | 60% | $167,208 |
| 2020 | 320 | 46 | 0% (0) | 53% | $118,542 |
| 2019 | 237 | 54 | 0% (0) | 34% | $46,518 |
| 2018 | 322 | 88 | 0% (0) | None | $42,295 |
| 2017 | 191 | 69 | 0% (0) | None | $15,446 |
| 2016 | 224 | 81 | 0% (0) | None | $8,791 |
| 2015 | 651 | 88 | None | None | $28,928 |
| 2014 | 714 | 76 | None | None | $27,841 |
| 2013 | 486 | 75 | None | 19% | $22,034 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Trulicity | 98 | $109,941 | $1,122 |
| Ozempic | 41 | $38,985 | $951 |
| Synjardy Xr | 31 | $18,073 | $583 |
| Jardiance | 21 | $13,183 | $628 |
| Xigduo Xr | 12 | $6,818 | $568 |
| Janumet Xr | 11 | $6,114 | $556 |
| Rifampin | 55 | $3,774 | $69 |
| Ultra-Fine Nano Pen Needle | 13 | $792 | $61 |
| Isoniazid | 66 | $552 | $8 |
| Metformin Hcl Er | 54 | $537 | $10 |
2022: 11 drugs
| Trulicity | 140 | $130,831 | $935 |
| Jardiance | 63 | $33,214 | $527 |
| Synjardy Xr | 37 | $20,584 | $556 |
| Ozempic | 22 | $19,794 | $900 |
| Rybelsus | 13 | $12,412 | $955 |
| Basaglar Kwikpen U-100 | 12 | $2,681 | $223 |
| Rifampin | 36 | $2,426 | $67 |
| Clotrimazole | 17 | $804 | $47 |
| Metformin Hcl Er | 62 | $405 | $7 |
| Isoniazid | 38 | $256 | $7 |
| Lisinopril | 14 | $125 | $9 |
2021: 8 drugs
| Trulicity | 93 | $79,892 | $859 |
| Jardiance | 61 | $33,184 | $544 |
| Synjardy Xr | 26 | $13,749 | $529 |
| Fiasp Flextouch | 11 | $1,200 | $109 |
| Rifampin | 13 | $663 | $51 |
| Clotrimazole | 12 | $646 | $54 |
| Isoniazid | 51 | $368 | $7 |
| Metformin Hcl Er | 71 | $262 | $4 |
2020: 7 drugs
| Jardiance | 43 | $25,605 | $595 |
| Trulicity | 27 | $23,477 | $870 |
| Synjardy Xr | 14 | $7,652 | $547 |
| Clotrimazole | 13 | $229 | $18 |
| Isoniazid | 34 | $228 | $7 |
| Metformin Hcl Er | 22 | $86 | $4 |
| Metformin | 29 | $76 | $3 |
2019: 7 drugs
| Jardiance | 17 | $8,200 | $482 |
| Lantus Solostar | 15 | $3,469 | $231 |
| Rifampin | 18 | $998 | $55 |
| Isoniazid | 71 | $542 | $8 |
| Metformin Hcl Er | 18 | $131 | $7 |
| Glipizide | 12 | $94 | $8 |
| Metformin | 14 | $43 | $3 |
2018: 6 drugs
| Trulicity | 19 | $13,900 | $732 |
| Lantus Solostar | 29 | $7,603 | $262 |
| Levemir Flextouch | 14 | $6,284 | $449 |
| Novolog Flexpen | 12 | $4,361 | $363 |
| Rifampin | 49 | $2,790 | $57 |
| Isoniazid | 155 | $1,074 | $7 |
2017: 3 drugs
| Lantus Solostar | 18 | $4,021 | $223 |
| Rifampin | 17 | $1,168 | $69 |
| Isoniazid | 120 | $794 | $7 |
2016: 1 drug
| Isoniazid | 149 | $951 | $6 |
2015: 20 drugs
| Tamsulosin | 17 | $549 | $32 |
| Pioglitazone | 12 | $549 | $46 |
| Levothyroxine | 22 | $533 | $24 |
| Atorvastatin | 26 | $276 | $11 |
| Fluticasone Propionate | 18 | $257 | $14 |
| Isoniazid | 34 | $243 | $7 |
| Sertraline | 12 | $243 | $20 |
| Simvastatin | 27 | $242 | $9 |
| Metformin | 20 | $215 | $11 |
| Hydrochlorothiazide | 25 | $152 | $6 |
| Amlodipine Besylate | 20 | $147 | $7 |
| Lisinopril | 30 | $140 | $5 |
| Glipizide | 14 | $128 | $9 |
| Gabapentin | 16 | $122 | $8 |
| Famotidine | 17 | $119 | $7 |
| Benazepril | 11 | $119 | $11 |
| Ranitidine | 13 | $107 | $8 |
| Alendronate | 11 | $82 | $7 |
| Losartan | 14 | $53 | $4 |
| Trazodone | 14 | $29 | $2 |
2014: 18 drugs
| Pioglitazone | 25 | $1,585 | $63 |
| Voltaren | 11 | $737 | $67 |
| Bupropion Hcl Sr | 13 | $480 | $37 |
| Levothyroxine | 29 | $454 | $16 |
| Metformin | 33 | $441 | $13 |
| Simvastatin | 46 | $414 | $9 |
| Atorvastatin | 16 | $382 | $24 |
| Tamsulosin | 20 | $345 | $17 |
| Fluticasone Propionate | 17 | $341 | $20 |
| Lisinopril | 34 | $333 | $10 |
| Amlodipine Besylate | 33 | $186 | $6 |
| Gabapentin | 25 | $164 | $7 |
| Glipizide | 21 | $156 | $7 |
| Ranitidine | 21 | $130 | $6 |
| Benazepril | 14 | $112 | $8 |
| Sertraline | 19 | $108 | $6 |
| Hydrochlorothiazide | 35 | $103 | $3 |
| Ibuprofen | 19 | $77 | $4 |
2013: 10 drugs
| Lantus | 18 | $3,315 | $184 |
| Levothyroxine | 36 | $405 | $11 |
| Metformin | 33 | $351 | $11 |
| Fluticasone Propionate | 12 | $320 | $27 |
| Lisinopril | 36 | $239 | $7 |
| Simvastatin | 18 | $191 | $11 |
| Amlodipine Besylate | 20 | $158 | $8 |
| Ranitidine | 12 | $99 | $8 |
| Hydrochlorothiazide | 21 | $72 | $3 |
| Ibuprofen | 15 | $59 | $4 |
Professional record
- NPI
- 1588621577
- Licence
- CA 16068California A16068: Cancelled
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 1333 Meridian Ave, San Jose, CA, 95125
- NPI first listed
- 2006-04-26
- NPI last updated
- 2009-02-24
This is when the NPI record was last certified, not a medical board exam.